Advances in clinical screening and early detection of the disease through the detection of prostate-specific antigen (PSA) have resulted in a 90% 5-year survival rate; yet, increase the risk for a man to face a diagnosis of PCa even when the tumor is benign or low-risk (Martin et al., 2018). This evidence concerns the gene PLAG1 and posterior cortical atrophy.